Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Nervous system problems (abnormality of the nervous system) and Hemifacial spasm.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 1 | Nervous system problems (abnormality of the nervous system) |
Biomarker and diagnostic research for clonic hemifacial spasm has been reported in the published literature.
4 FDA-approved treatments are available for clonic hemifacial spasm, including ONABOTULINUMTOXINA (BOTOX COSMETIC, approved 1991), BOTULINUM TOXIN TYPE A (DYSPORT, approved 2009), and INCOBOTULINUMTOXINA (XEOMIN, approved 2010).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Estimated prevalence: 1-5 in 10,000 (Uncommon).
3 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE4, 1 PHASE3. Research is primarily sponsored by academic and government institutions.
133 publications have been identified in PubMed for clonic hemifacial spasm. Kisho has analyzed 91 by research type. Research spans Clinical Trial Publication (32%), Review / Meta-Analysis (24%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 29 |
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 2:36 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about clonic hemifacial spasm
DAXXIFY |
BOTULINUM TOXIN TYPE A |
— |
2022 |
Available |
XEOMIN | INCOBOTULINUMTOXINA | — | 2010 | Available |
DYSPORT | BOTULINUM TOXIN TYPE A | — | 2009 | Available |
MYOBLOC | RIMABOTULINUMTOXINB | — | 2000 | Available |
BOTOX COSMETIC | ONABOTULINUMTOXINA | — | 1991 | Available |
3 trials found
32%
Research summaries | 22 | 24% |
Disease patterns and progression | 16 | 18% |
Patient case studies | 9 | 10% |
Laboratory research | 8 | 9% |
Testing and diagnosis research | 5 | 5% |
Other research | 2 | 2% |
Kishi A (2026). [PMID: 40488245](https://pubmed.ncbi.nlm.nih.gov/40488245/). *Ophthalmic Plast Reconstr Surg*. [Case Report / Case Series]
Sekiya T (2026). [PMID: 42037057](https://pubmed.ncbi.nlm.nih.gov/42037057/). *Br J Neurosurg*. [Review / Meta-Analysis]
Yaka EC (2026). [PMID: 41934473](https://pubmed.ncbi.nlm.nih.gov/41934473/). *Int Ophthalmol*. [Clinical Trial Publication]
Jesuthasan A (2025). [PMID: 40640398](https://pubmed.ncbi.nlm.nih.gov/40640398/). *J Neurol*. [Review / Meta-Analysis]
Chua-See PD (2025). [PMID: 41357053](https://pubmed.ncbi.nlm.nih.gov/41357053/). *Journal of the ASEAN Federation of Endocrine Societies*. [Case Report / Case Series]
Menabbawy AA (2025). [PMID: 39775263](https://pubmed.ncbi.nlm.nih.gov/39775263/). *Acta neurochirurgica*. [Diagnostic / Biomarker]
Lara-Barrera PD (2025). [PMID: 40058689](https://pubmed.ncbi.nlm.nih.gov/40058689/). *Archivos de la Sociedad Espanola de Oftalmologia*. [Clinical Trial Publication]
Sampaio Rocha-Filho PA (2025). [PMID: 40711126](https://pubmed.ncbi.nlm.nih.gov/40711126/). *Toxins (Basel)*. [Review / Meta-Analysis]
Shahabinejad E (2025). [PMID: 40328139](https://pubmed.ncbi.nlm.nih.gov/40328139/). *Clin Neurol Neurosurg*. [Review / Meta-Analysis]
Zachem TJ (2025). [PMID: 40753669](https://pubmed.ncbi.nlm.nih.gov/40753669/). *J Clin Neurosci*. [Review / Meta-Analysis]